Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
861 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.
Richeldi L, Azuma A, Cottin V, et al. · N Engl J Med · 2025Randomized Controlled Trial, Multicenter Study
- Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.
Corte TJ, Behr J, Cottin V, et al. · Am J Respir Crit Care Med · 2025Clinical Trial, Phase II, Randomized Controlled Trial
- Incidence and prevalence of idiopathic pulmonary fibrosis: a systematic literature review and meta-analysis.
Golchin N, Patel A, Scheuring J, et al. · BMC Pulm Med · 2025Systematic Review, Meta-Analysis
- Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L, du Bois RM, Raghu G, et al. · N Engl J Med · 2014Clinical Trial, Phase III, Multicenter Study
- Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, et al. · N Engl J Med · 2019Clinical Trial, Phase III, Multicenter Study
- Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.
Nathan SD, Smith P, Deng C, et al. · N Engl J Med · 2026Randomized Controlled Trial, Multicenter Study
- Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP, Ponnuswamy A, Dutta P, et al. · BMC Pulm Med · 2021Comparative Study, Meta-Analysis
- A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models.
Ren F, Aliper A, Chen J, et al. · Nat Biotechnol · 2025Randomized Controlled Trial, Clinical Trial, Phase I
- Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial.
Raghu G, Richeldi L, Fernández Pérez ER, et al. · JAMA · 2024Clinical Trial, Phase III, Multicenter Study
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW, Albera C, Bradford WZ, et al. · Lancet · 2011Comparative Study, Multicenter Study
- A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial.
Xu Z, Ren F, Wang P, et al. · Nat Med · 2025Randomized Controlled Trial, Clinical Trial, Phase II
- Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.
Hutchinson J, Fogarty A, Hubbard R, et al. · Eur Respir J · 2015Systematic Review
- Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis.
Kou M, Jiao Y, Li Z, et al. · Eur J Clin Pharmacol · 2024Meta-Analysis, Systematic Review
- Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Petnak T, Lertjitbanjong P, Thongprayoon C, et al. · Chest · 2021Meta-Analysis, Systematic Review
- A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE, Bradford WZ, Castro-Bernardini S, et al. · N Engl J Med · 2014Clinical Trial, Phase III, Multicenter Study
- Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.
Justice JN, Nambiar AM, Tchkonia T, et al. · EBioMedicine · 2019Clinical Trial
- Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis.
Richeldi L, Azuma A, Cottin V, et al. · N Engl J Med · 2022Clinical Trial, Phase II, Randomized Controlled Trial
- Comorbidities in the idiopathic pulmonary fibrosis and progressive pulmonary fibrosis trial population: a systematic review and meta-analysis.
Walters TM, Leong MCH, Montesi SB, et al. · Eur Respir Rev · 2025Systematic Review, Meta-Analysis
- Transcriptomics of interstitial lung disease: a systematic review and meta-analysis.
He D, Guler SA, Shannon CP, et al. · Eur Respir J · 2025Meta-Analysis, Systematic Review
- A fibroblast-dependent TGF-β1/sFRP2 noncanonical Wnt signaling axis promotes epithelial metaplasia in idiopathic pulmonary fibrosis.
Cohen ML, Brumwell AN, Ho TC, et al. · J Clin Invest · 2024Clinical Trial, Research Support, U.S. Gov't, P.H.S.
- Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis.
Nathan SD, Smith P, Deng C, et al. · N Engl J Med · 2026Randomized Controlled Trial, Clinical Trial, Phase III
- Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial.
Lancaster L, Cottin V, Ramaswamy M, et al. · Am J Respir Crit Care Med · 2024Randomized Controlled Trial, Multicenter Study
- Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial.
Oldham JM, Azuma A, Kreuter M, et al. · Am J Respir Crit Care Med · 2026Randomized Controlled Trial, Multicenter Study
- Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability.
Nambiar A, Kellogg D, Justice J, et al. · EBioMedicine · 2023Randomized Controlled Trial, Clinical Trial, Phase I
- Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, et al. · Lancet Respir Med · 2020Multicenter Study, Randomized Controlled Trial
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.